Patent EP0628806A2 successfully refreshed from Google Patents.
Patent EP0225409A1 successfully refreshed from Google Patents.
EP0225409A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Organic amine phosphonic acid complexes for the treatment of calcific tumors
Assignee: Dow Chemical Co
•
Filing: 1985-12-02
•
Granted: —
•
Expires: 2005-12-02
Abstract
Abstract Particle-emitting radionuclides (Y-90 and In-115) have been complexed with phosphonic acid derivatives of organic amine or substituted organic amine compounds wherein the nitrogen and phosphorus are interconnected by an alkylene group. These complexes have been found useful in the treatment of calcific tumors in animals.
Inventors
- 👤 Jaime Simon
- 👤 Wynn A. Volkert
- 👤 David A. Wilson
- 👤 David E. Troutner
- 👤 William F. Goeckeler
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 12:46
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0489; A61K51/0474; A61K51/0478; C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3808; C07F9/3817; A61K2121/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
46 words
A therapeutically effective complex of a paticle-emitting radionuclide of yttrium or indium with an aminophosphonic acid derivative which is ethylene- diaminetetramethylenephosphonic acid (EDTMP), diethylenetriaminepentamethylenephosphonic acid (DTPMP), hydroxyethylethylenediaminetrimethylenephosphonic acid (HEEDTMP), nitrilotrimethylenephosphonic acid (NTMP) or tris(2-aminoethyl) aminehexamethylenephosphonic acid (TTHMP) or a physiologically acceptable salt of such a complex.
Claim 2
Dependent Claim
46 words
A therapeutically effective complex of a paticle-emitting radionuclide of yttrium or indium with an aminophosphonic acid derivative which is ethylene- diaminetetramethylenephosphonic acid (EDTMP), diethylenetriaminepentamethylenephosphonic acid (DTPMP), hydroxyethylethylenediaminetrimethylenephosphonic acid (HEEDTMP), nitrilotrimethylenephosphonic acid (NTMP) or tris(2-aminoethyl) aminehexamethylenephosphonic acid (TTHMP) or a physiologically acceptable salt of such a complex.
Claim 3
Dependent Claim
14 words
A complex as claimed in Claim 1, characterized in that said radionuclide is Y-90.
Claim 4
Dependent Claim
14 words
A complex as claimed in Claim 1, characterized in that said radionuclide is In-115.
Claim 5
Dependent Claim
18 words
A complex as claimed any one of the preceding claims, which also comprises an additional rare earth radionuclide.
Claim 6
Dependent Claim
23 words
A complex as claimed in Claim 4, wherein the additional rare earth radionuclide is an isotope of gadolinium, holmium, lutetium, samarium or ytterbium.
Claim 7
Dependent Claim
25 words
A complex as claimed in Claim 5, wherein the additional rare earth radionuclide is gadolinium-159 (Gd-159), holmium-166 (Ho-166), lutetium-177 (Lu-177), samarium-153 (Sm-153) or ytterbium-175 (Yb-175).
Claim 8
Dependent Claim
13 words
A complex as claimed in Claim 6, wherein the additional radionuclide is Sm-153.
Claim 9
Dependent Claim
23 words
A complex as claimed in any one of Claims 1 to 7, characterized in that the aminophosphonic acid derivative is ethylenediaminetetramethylenephosphonic acid (EDTMP).
Claim 10
Dependent Claim
23 words
A complex as claimed in any one of Claims 1 to 7, characterized in that the aminophosphonic acid derivative is diethylenetriaminepentamethylenephosphonic acid (DTPMP).
Claim 11
Dependent Claim
24 words
A complex as claimed in any one of Claims 1 to 7, characterized in that the aminophosphonic acid derivative is hydroxyethylethylenediaminetrimethylene phosphonic acid (HEEDTMP).
Claim 12
Dependent Claim
23 words
A complex as claimed in any one of Claims 1 to 7, characterized in that said aminophosphonic acid derivative is nitrilotrimethylenephosphonic acid (NTMP).
Claim 13
Dependent Claim
24 words
A complex as claimed in any one of Claims 1 to 7, characterized in that the aminophosphonic acid derivative is tris(2-aminoethyl) aminehexamethylenephosphonic acid (TTHMP)>
Claim 14
Dependent Claim
40 words
A process for the preparation of a therapeutically effective complex as claimed in Claim 1, characterized in that a radionuclide which is Y-90 or In-115 is contacted with an aminophosphonic acid derivative which is EDTMP, DTPMP, HEEDTMP, NTMP or TTHMP.
Claim 15
Dependent Claim
27 words
A process as claimed in Claim 13, wherein the said contact is carried out in the presence of water at a pH of from 5 to 11.
Claim 16
Dependent Claim
20 words
A process as claimed in Claim 13 or Claim 14, wherein the said contact is carried out at elevated temperature.
Claim 17
Dependent Claim
27 words
A process as claimed in any one of Claims 13 to 15, including the step of adjusting the pH of the complex to from 7 to 8.
Claim 18
Dependent Claim
21 words
A process as claimed in any one of Claims 13 to 16, characterized in that said aminophosphonic acid derivative is EDTMP.
Claim 19
Dependent Claim
21 words
A process as claimed in any one of Claims 13 to 16, characterized in that the aminophosphonic acid derivative is DTPMP.
Claim 20
Dependent Claim
21 words
A process as claimed in any one of Claims 13 to 16, characterized in that the aminophosphonic acid derivative is HEEDTMP.
Claim 21
Dependent Claim
21 words
A process as claimed in any one of Claims 13 to 16, characterized in that the aminophosphonic acid derivative is NTMP.
Claim 22
Dependent Claim
21 words
A process as claimed in any one of Claims 13 to 16, characterized in that the aminophosphonic acid derivative is TTHMP.
Claim 23
Dependent Claim
33 words
A process as claimed in any one of Claims 13 to 16, characterized in that the aminophosphonic and said radionuclide acid derivative are contacted in a molar ratio of from 0.1:1 to 3000:1.
Claim 24
Dependent Claim
19 words
A complex as claimed in any one of Claims 1 to 12, for use in the treatment of cancer.
Claim 25
Dependent Claim
26 words
The use of a complex as claimed in any one of Claims 1 to 12, in the manufacture of a medicament for the treatment of cancer.
References Cited (Backward Citations)
EP0164843A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.